4.7 Article

EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 74, Issue 7, Pages 1327-1339

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2014-206971

Keywords

-

Categories

Funding

  1. AbbVie
  2. BMS
  3. GE
  4. Janssen
  5. MSD
  6. Pfizer
  7. Roche
  8. UCB
  9. Novartis
  10. Amgen
  11. AstraZeneca
  12. Augurex
  13. Boehringer Ingelheim
  14. Celgene
  15. Centocor
  16. Chugai
  17. Covagen
  18. Daiichi
  19. Eli-Lilly
  20. Galapagos
  21. GSK
  22. Janssen Biologics
  23. Merck
  24. Novo-Nordisk
  25. Otsuka
  26. Sanofi-Aventis
  27. Vertex
  28. Sandoz
  29. Wyeth
  30. Spanish Foundation of Rheumatology
  31. ESAOTE
  32. Abbott
  33. Lilly
  34. Norpharma
  35. Mundipharma
  36. Hospira
  37. Orion
  38. Takeda

Ask authors/readers for more resources

A taskforce comprised of an expert group of 21 rheumatologists, radiologists and methodologists from 11 countries developed evidence-based recommendations on the use of imaging in the clinical management of both axial and peripheral spondyloarthritis (SpA). Twelve key questions on the role of imaging in SpA were generated using a process of discussion and consensus. Imaging modalities included conventional radiography, ultrasound, magnetic resonance imaging, computed tomography (CT), positron emission tomography, single photon emission CT, dual-emission x-ray absorptiometry and scintigraphy. Experts applied research evidence obtained from systematic literature reviews using MEDLINE and EMBASE to develop a set of 10 recommendations. The strength of recommendations (SOR) was assessed by taskforce members using a visual analogue scale. A total of 7550 references were identified in the search process, from which 158 studies were included in the systematic review. Ten recommendations were produced using research-based evidence and expert opinion encompassing the role of imaging in making a diagnosis of axial SpA or peripheral SpA, monitoring inflammation and damage, predicting outcome, response to treatment, and detecting spinal fractures and osteoporosis. The SOR for each recommendation was generally very high (range 8.9-9.5). These are the first recommendations which encompass the entire spectrum of SpA and evaluate the full role of all commonly used imaging modalities. We aimed to produce recommendations that are practical and valuable in daily practice for rheumatologists, radiologists and general practitioners.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available